The United Kingdom regulates medical devices through the Medicines and Healthcare products Regulatory Agency (MHRA), not the European Commission. Since Brexit, Great Britain (England, Scotland, Wales) is a separate regulatory jurisdiction from the EU, with its own conformity mark. UKCA. And its own rules. In 2026 the UK is still in a long transition phase in which CE-marked devices continue to be accepted on the Great Britain market under MHRA-set conditions, while a modernised UK framework is being consulted on. Northern Ireland follows EU MDR rules under the Windsor Framework. Because UK-specific rules are actively changing, every concrete deadline and procedural detail in this post must be re-verified against current MHRA guidance before you act on it.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • The MHRA is the UK competent authority for medical devices. It plays the role that, in the EU, is split between the European Commission, national competent authorities, and the MDCG.
  • UKCA is the UK conformity mark. It is the UK's counterpart to the CE mark, but it is assessed against UK domestic rules, not against Regulation (EU) 2017/745.
  • CE-marked devices continue to be recognised for placing on the Great Britain market during an extended transition period set by the MHRA. The exact end date of this recognition has been revised more than once and must be checked against current MHRA guidance before you plan around it.
  • Northern Ireland is not on the UK regulatory track for medical devices. Under the Windsor Framework, devices placed on the Northern Ireland market must comply with EU MDR and carry the CE mark.
  • For most EU startups in 2026, the right strategy is EU first under MDR, UK later under whatever framework is finalised. Not both at once.

Why the UK question keeps coming up

Every few months, an EU founder in a first call asks a version of the same question. "We are going for CE marking under MDR. The UK is our next market. Do we need UKCA? Can we still use CE? What does the MHRA actually want?" The honest answer in 2026 is that the rules are in motion, the public statements from MHRA have shifted more than once, and nobody should be making firm multi-year UK plans based on a blog post alone. Including this one.

That does not make the UK question unanswerable. The structural picture is stable even while the dates move. Once a founder understands the structure, they can read any current MHRA guidance document and slot it into the right place. That structure is what this post explains.

A second reason the UK question keeps coming up is simpler. The UK market is real. The NHS is a single large buyer, private healthcare in London and the South East has genuine budget, and the cultural distance for an EU startup is smaller than the cultural distance to the US. For many founders, the UK is the first market they think about after the EU. That instinct is not wrong. It just needs a regulatory plan that matches the current reality, not the pre-Brexit reality or the 2019 reality or the originally planned UKCA-only reality.

The UK regulatory framework in general terms

The UK's medical device regulatory framework has three layers in 2026.

Layer 1. The underlying UK statute. UK medical device law is rooted in domestic UK legislation derived from the pre-MDR EU Medical Device Directives, carried over into UK law at the end of the Brexit transition. This underlying statute is what the MHRA enforces and what a UKCA assessment is ultimately conducted against. It resembles the pre-MDR directive logic more than it resembles Regulation (EU) 2017/745.

Layer 2. MHRA transition instruments. On top of the underlying statute, the MHRA has issued a sequence of transition arrangements governing when and how CE-marked devices continue to be accepted on the Great Britain market, and how UKCA will be phased in. These are the instruments that have been revised repeatedly. Anyone making UK plans in 2026 needs to read the latest MHRA guidance directly, not a secondary source.

Layer 3. The future UK framework. The MHRA has publicly committed to a modernised UK medical device regulatory framework, shaped by UK-led consultations and intended to reflect UK policy priorities rather than track the MDR line by line. As of 2026 this future framework is still being finalised in parts and phased in over time. The exact shape of the end-state regime, and which elements will match MDR versus diverge from it, is not fully settled.

The key insight for an EU founder is this: the UK framework is not a fork of the MDR. It is a parallel national system that shares a common ancestor with the MDR (the old directives) and that will increasingly diverge as the UK's own reforms land.

UKCA marking and the CE marking recognition transition

UKCA (UK Conformity Assessed) is the UK's own conformity mark. A device that carries a valid UKCA mark has been assessed, under UK rules, as compliant with UK requirements for placing on the Great Britain market. It is the UK equivalent of the CE mark in function, but not in legal basis.

When the UK left the EU, the original government plan was a hard switch from CE to UKCA for the Great Britain market on a defined date. That hard switch did not happen on the original schedule. Instead, the MHRA extended the period during which CE-marked devices, assessed under the current EU framework, can continue to be placed on the Great Britain market under defined conditions. That extension has been revised more than once.

As a practical matter in 2026, a device that holds valid CE marking under Regulation (EU) 2017/745 can, subject to the current MHRA transition rules, continue to be placed on the Great Britain market without a separate UKCA assessment. But the operative words are "subject to the current MHRA transition rules." Those rules include conditions, deadlines, and registration obligations that change. Before you plan a launch, a procurement deal, or a board slide on UK revenue, you or your regulatory advisor must read the live MHRA guidance and confirm what still applies.

The main thing to internalise: CE recognition in the UK is a transitional choice by the MHRA, not a permanent right. It can be extended again. It can be narrowed. It will eventually end. Your UK strategy needs to accommodate that reality.

The MHRA's role

The MHRA is the UK government agency responsible for medicines, medical devices, and blood products. For medical devices it is simultaneously:

  • The competent authority that designates and supervises UK Approved Bodies (the UK counterpart to EU Notified Bodies) that issue UKCA certificates.
  • The national registrar for medical devices placed on the UK market, including devices sold under current CE recognition.
  • The authority that receives vigilance reports and runs post-market surveillance at national level.
  • The rule-maker publishing guidance on how UK medical device law applies in specific situations.
  • The lead body running the consultations that will shape the future UK framework.

Compared to the EU, the UK concentrates more functions in a single national agency. There is no MDCG equivalent whose guidance you must track in parallel. There is no 27-state patchwork of national language and labelling rules. Practically, this means one authority to read, one registration portal to learn, and one published set of fees. But also less cross-jurisdiction pressure to keep UK rules aligned with anyone else's.

How it compares to MDR

At the structural level, UK medical device regulation and the MDR aim at the same outcome: a safe and effective device, manufactured under a controlled quality system, backed by clinical evidence, supported by post-market surveillance, and marked to show conformity. The building blocks are familiar.

Where they differ:

  • Legal instrument. MDR is Regulation (EU) 2017/745. A directly applicable EU regulation. UK law is domestic UK legislation derived from the pre-MDR directives, with MHRA transition instruments layered on top. The legal texts are not the same and must be cited separately.
  • Clinical evidence intensity. The MDR tightened clinical evidence expectations significantly over the previous directive regime, especially around equivalence and post-market clinical follow-up. The current UK framework still sits closer to the pre-MDR baseline in many respects. The direction of travel in the UK reforms may or may not close this gap. That depends on which elements of the MHRA's future framework land in their current draft form.
  • Post-market surveillance and vigilance. MDR has a very prescriptive PMS architecture (PMS plan, PMS report or PSUR, PMCF, clear vigilance timelines). The UK PMS regime is lighter at the statute level but the MHRA expects manufacturers to report and act on incidents on the UK market through MHRA channels.
  • Representation. Under MDR, a non-EU manufacturer needs an EU authorised representative. Under UK rules, a non-UK manufacturer needs a UK Responsible Person established in the UK. These are separate appointments. An EU AR cannot cover UK obligations, and a UK Responsible Person does not replace an EU AR.
  • Databases. MDR uses EUDAMED for registrations and public transparency (to the extent modules are live). The UK uses MHRA's own device registration system, not EUDAMED.

In practice, a startup that has built its technical documentation and QMS around MDR will find most of the substance is reusable for a UK submission. The work is in adapting the references, filing separately, and meeting UK-specific administrative obligations. Not in redoing clinical evaluation from scratch.

Northern Ireland specifics

Northern Ireland is the exception inside the UK. Under the Windsor Framework (the successor arrangement to the Northern Ireland Protocol), Northern Ireland follows EU rules for goods in several areas, including medical devices. That means:

  • A device placed on the Northern Ireland market must comply with EU MDR and must carry the CE mark, not the UKCA mark.
  • The EU authorised representative requirement applies for non-EU manufacturers placing devices on the Northern Ireland market.
  • Vigilance and post-market surveillance for devices on the Northern Ireland market involve both MHRA (as the UK national authority) and the EU framework.

For an EU startup that already has MDR CE marking, accessing Northern Ireland is relatively frictionless from a regulatory perspective. The same mark, the same regulation, plus the UK-side administrative overlay that the MHRA requires. Accessing Great Britain (England, Scotland, Wales) is the separate question that this post has been addressing.

The exact interaction between Northern Ireland rules and Great Britain rules. Particularly for movement of goods between NI and GB. Is governed by current Windsor Framework instruments that have themselves been revised. Verify against current UK and EU guidance before making operational plans.

When to pursue UK market access

For an EU MedTech startup in 2026, the case for pursuing UK market access in the first two years is usually weak. The case for pursuing it later is often strong. The deciding factors:

  1. Revenue proximity. Is there a specific UK buyer. An NHS trust, a private group, a distributor. With a concrete purchase intent and a timeline? Revenue in hand justifies regulatory investment. Speculative UK expansion does not.
  2. Resource bandwidth. Can your regulatory and quality team genuinely take on a second jurisdiction without degrading your MDR work? Half-finished compliance in two jurisdictions is worse than complete compliance in one.
  3. Framework clarity. Is the current MHRA transition guidance clear enough that you can plan a two-year UK strategy on it, or is it still in flux? The honest answer in early 2026 is "still in flux for anything requiring UKCA involvement, stable enough for CE-recognition-based market access under the current transition."
  4. Classification and device type. Higher-risk devices face more assessment burden in any jurisdiction, and the UK approved body capacity picture has been tight in specific classes. Verify availability before committing to a timeline.

The default recommendation from Tibor and Felix is EU first under MDR, UK next under current CE recognition once there is real UK demand, and a formal UK assessment only when either the buyer requires it contractually or the MHRA transition rules force the question.

Cost and timeline reality

Because UK rules are in transition, cost and timeline estimates carry more uncertainty than their MDR equivalents. With that caveat, directional ranges Tibor sees for EU startups in 2026:

  • Appointing a UK Responsible Person. A low four-figure to mid five-figure annual retainer is typical, depending on scope and the number of devices covered.
  • MHRA device registration. Per-device and per-category fees apply. Fee schedules are published by the MHRA and change periodically. Check current fees directly.
  • UK Approved Body assessment for UKCA (when required). Broadly comparable in order of magnitude to EU Notified Body fees for equivalent device classes, with the caveat that UK approved body capacity has been tighter than EU NB capacity in some classes, which can affect timelines more than fees.
  • Documentation and labelling adaptation. Usually a smaller incremental line than the assessment fees themselves, especially if the EU technical documentation is already in good shape.
  • Ongoing compliance. Vigilance, PMS, and registration upkeep on the UK side are additive to your EU obligations, not a replacement.

Directional only. Live quotes and published MHRA fees are the numbers you should put on a board slide.

Honest limits of current knowledge. A 2026 snapshot

Tibor and Felix want to be explicit about what this post is and is not.

This post is a structural explanation of the UK medical device regulatory landscape and how it relates to the MDR, written for an EU founder trying to make sensible strategic decisions. It is accurate at the structural level.

This post is not, and cannot be, a live reference for the current UK medical device legal instruments, MHRA transition deadlines, UK Approved Body designations, Windsor Framework operational details, or MHRA fee schedules. Those specifics change, and the project's ground truth catalog covers the EU MDR regime in depth, not the UK regime. Any blog post that claims to be a definitive current source on UK rules, including this one, must be read against live MHRA guidance published on the MHRA's own website before you act on it.

The safe rule: use this post to understand the shape of the UK picture. Use current MHRA guidance to understand the numbers and dates. Use a regulatory advisor with live UK practice to confirm your specific device, class, and timeline before you spend money.

The Subtract to Ship angle

The Subtract to Ship discipline is to strip every activity, document, and spend that does not trace back to a requirement you actually have. For UK market access, that discipline is unusually valuable, because the temptation is to treat "the UK" as a parallel MDR programme and double-book yourself on work nobody is asking for yet.

Three subtractions Felix recommends for most EU startups in 2026:

  1. Subtract speculative UKCA work. Unless you have a signed or near-signed UK buyer whose procurement requires UKCA today, do not spend on UK Approved Body assessment today. Use the current CE recognition route, keep your MDR house in order, and revisit when real demand lands.
  2. Subtract parallel UK documentation streams. Maintain one master technical file aligned to MDR. Generate UK-specific views (references, labelling inserts, UK Responsible Person details) as overlays, not as a second file. Two files means two things to keep in sync and two things that can fall out of sync.
  3. Subtract "nice-to-have" UK activities. Attending every MHRA webinar, subscribing to every UK regulatory newsletter, joining every UK working group. These can feel productive and do nothing for your certificate. Pick one primary MHRA information channel (the MHRA's own guidance pages) and one trusted regulatory advisor. Drop the rest until you have an active UK programme.

What you add back in, deliberately, is a quarterly re-read of the current MHRA transition guidance. The goal is not to react to every change, it is to catch a change that moves the transition end date or the UKCA trigger inside your planning horizon.

Reality Check. Where do you stand on UK market access?

  1. Do you have a concrete UK buyer or distribution partner with a stated timeline, or is the UK still a line on a slide?
  2. Have you read the current MHRA guidance on CE recognition for Great Britain within the last three months, or are you working from an older version?
  3. Have you confirmed whether your device, in its current classification, needs UK Approved Body assessment now, or is still covered under CE recognition for the Great Britain market?
  4. If you sell into Northern Ireland, have you mapped the CE-mark obligation under EU MDR and the MHRA-side administrative obligations separately?
  5. Have you appointed a UK Responsible Person, or confirmed in writing that you do not yet need one under current rules?
  6. Is your UK plan an overlay on your MDR plan, or has it quietly turned into a parallel programme that is competing for the same regulatory bandwidth?
  7. Do you have a live regulatory advisor with current UK practice, or are you relying on a blog post, a conference talk, or a document more than six months old?

Any "no" or "not sure" is a flag. None of them require immediate spend. All of them require clarification before you commit to a UK launch date in a board deck or a term sheet.

Frequently Asked Questions

Can an EU startup with MDR CE marking sell in the UK in 2026? In general, yes. CE-marked devices can currently be placed on the Great Britain market under the MHRA's transition arrangements, and on the Northern Ireland market under the Windsor Framework. The specific conditions, registration requirements, and end date of the Great Britain transition must be verified against current MHRA guidance before you rely on them.

Is UKCA marking mandatory yet for medical devices? Not in the way originally planned. The MHRA has extended the period during which CE-marked devices remain acceptable on the Great Britain market, so a mandatory UKCA-only state has not arrived on the original schedule. That may change, and it will not change silently. The MHRA publishes transition guidance that you should monitor.

Does Northern Ireland use UKCA or CE? Northern Ireland uses CE marking under EU MDR for medical devices, by virtue of the Windsor Framework. UKCA is the Great Britain mark, not an all-UK mark.

Is the MHRA the same thing as an EU Notified Body? No. The MHRA is the UK government regulator. Closer in role to a national competent authority combined with several Commission-level functions. UK Approved Bodies, designated by the MHRA, are the UK counterpart to EU Notified Bodies and are the organisations that issue UKCA certificates.

Should an EU startup pursue UKCA now or wait? For most EU startups in 2026 with limited regulatory bandwidth, the honest answer is wait. Unless a specific UK buyer requires it now. Build your MDR foundation, use CE recognition for UK market access while it is available, and revisit the UKCA question when UK revenue is real or the transition rules change.

Where can I find current MHRA guidance? Directly on the MHRA's own website (gov.uk pages managed by the MHRA for medical devices). Do not rely on blog posts, aggregator sites, or conference slides for operational details. Use them to orient, then verify on gov.uk before acting.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Consolidated text, EUR-Lex.
  2. UK medical device law as administered by the MHRA. Live guidance and transition instruments published on the MHRA's own pages at gov.uk. (These are the authoritative source for all current UK-specific deadlines, registration obligations, fee schedules, and UK Approved Body designations. This post does not reproduce specific UK legal instrument citations or dates because UK-specific rules fall outside the project's regulatory ground truth catalog and are subject to ongoing change.)
  3. MDCG 2021-24, Guidance on classification of medical devices, October 2021. Referenced as the MDR-side classification counterpart when comparing UK and MDR classification approaches.
  4. EN ISO 13485:2016 + A11:2021, Medical devices. Quality management systems. Requirements for regulatory purposes. Referenced as the QMS standard underpinning both MDR and UK expectations.

This post is part of the FDA and International Market Access series in the Subtract to Ship: MDR blog. Authored by Tibor Zechmeister and Felix Lenhard. Important: UK medical device rules are actively evolving under ongoing MHRA consultations and transition instruments. Before you make any operational, financial, or legal decision based on this post. Pricing a UK launch, appointing a UK Responsible Person, committing to a UKCA timeline, or planning Northern Ireland market entry. Check the current MHRA guidance directly at gov.uk and confirm specifics with a regulatory advisor who actively practises in the UK. Use this post to understand the shape of the landscape, not as a live legal or regulatory reference.